Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.42 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.42 |
| ▸ | DUT | P33316 | 6/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28817721 | 0.84 | SLC28A1 (0.37) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL2898597 | 0.81 | SLC28A1 (0.38) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL15285199 | 0.81 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL4324101 | 0.81 | SLC28A1 (0.38) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL28786348 | 0.81 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL51723 | 0.81 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL8952265 | 0.80 | SLC28A1 (0.39) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL2242410 | 0.80 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL65485 | 0.80 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL414705 | 0.80 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530490-B2 | Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| EP-2295414-B1 | URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2295414-A1 | NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082163-A1 | NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY | SNRPB2, SNRPA1, DUT | SLC28A1 93/4885SLC28A2 57/4885SLC29A1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.